FDA approves new macular degeneration treatment

Share this article:

The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.

Eylea, which is manufactured by Regeneron Pharmaceuticals, is a slightly less expensive treatment, costing $1,850 per injection, versus $1,950 for Genentech's Lucentis.

Both Lucentis and Eylea are still more expensive than the cancer drug Avastin, also made by Genentech. Avastin, which was recently pulled by the FDA as a breast cancer treatment option, is used as an off-label drug to treat macular degeneration, and accounts for over half of that market, The New York Times reports. Avastin costs only $50 per dose, but has been hampered recently due to reports that tainted vials of the drug infected users with Streptococcus endophthalmitis.

 

Share this article:

More in News

Profile: AHCA's money player

Profile: AHCA's money player

If there's a prevailing theme around the hours American Health Care Association senior fellow Elise Smith keeps, it's that they are constant.

Residents cheer tractor parade

Residents cheer tractor parade

Many residents of the Oskaloosa Care Center in southern Iowa used to be farmers. They're reminded of their past by the cornfield next to the nursing home — and, once ...

No need for injury

No need for injury

Due to dynamic factors in moving residents, facilities must invest wisely in lifts, slings and batteries to make sure workers stay safe while performing transfers